Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Slifstein

Showing results (101-110 of 131) with videos related to

Pageof 14
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 18, 2008
Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallyprideLawrence S Kegeles, Mark Slifstein, W Gordon Frankle, et al.
Nuclear Medicine and Biology|May 4, 2015
Radiosynthesis and initial characterization of a PDE10A specific PET tracer [18F]AMG 580 in non-human primatesDah-Ren Hwang, Essa Hu, Jennifer R Allen, et al.
Biological Psychiatry|May 4, 2010
Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patientsDaniel R Rosell, Judy L Thompson, Mark Slifstein, et al.
The American Journal of Psychiatry|May 3, 2005
Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652W Gordon Frankle, Ilise Lombardo, Antonia S New, et al.
EJNMMI Research|June 28, 2015
An evaluation of the brain distribution of [(11)C]GSK1034702, a muscarinic-1 (M 1) positive allosteric modulator in the living human brain using positron emission tomographyKhanum Ridler, Vincent Cunningham, Mickael Huiban, et al.
Journal of Psychopharmacology (Oxford, England)|March 12, 2016
A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophreniaRagy R Girgis, Jared X Van Snellenberg, Andrew Glass, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 27, 2019
Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography studyDiana Martinez, Mark Slifstein, David Matuskey, et al.
Synapse (New York, N.Y.)|January 4, 2012
Affinity and selectivity of [¹¹C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivoJean-Dominique Gallezot, John D Beaver, Roger N Gunn, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 11, 2004
Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behaviorDiana Martinez, Allegra Broft, Richard W Foltin, et al.
Synapse (New York, N.Y.)|June 21, 2011
Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1Roger N Gunn, Venkatesha Murthy, Ana M Catafau, et al.
Pageof 14

Showing results (101-110 of 131) with videos related to

Sort By:
Pageof 14
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 18, 2008
Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallyprideLawrence S Kegeles, Mark Slifstein, W Gordon Frankle, et al.
Nuclear Medicine and Biology|May 4, 2015
Radiosynthesis and initial characterization of a PDE10A specific PET tracer [18F]AMG 580 in non-human primatesDah-Ren Hwang, Essa Hu, Jennifer R Allen, et al.
Biological Psychiatry|May 4, 2010
Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patientsDaniel R Rosell, Judy L Thompson, Mark Slifstein, et al.
The American Journal of Psychiatry|May 3, 2005
Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652W Gordon Frankle, Ilise Lombardo, Antonia S New, et al.
EJNMMI Research|June 28, 2015
An evaluation of the brain distribution of [(11)C]GSK1034702, a muscarinic-1 (M 1) positive allosteric modulator in the living human brain using positron emission tomographyKhanum Ridler, Vincent Cunningham, Mickael Huiban, et al.
Journal of Psychopharmacology (Oxford, England)|March 12, 2016
A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophreniaRagy R Girgis, Jared X Van Snellenberg, Andrew Glass, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 27, 2019
Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography studyDiana Martinez, Mark Slifstein, David Matuskey, et al.
Synapse (New York, N.Y.)|January 4, 2012
Affinity and selectivity of [¹¹C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivoJean-Dominique Gallezot, John D Beaver, Roger N Gunn, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 11, 2004
Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behaviorDiana Martinez, Allegra Broft, Richard W Foltin, et al.
Synapse (New York, N.Y.)|June 21, 2011
Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1Roger N Gunn, Venkatesha Murthy, Ana M Catafau, et al.
Pageof 14